Deroy & Devereaux Private Investment Counsel Inc. Acquires Shares of 109,960 Enovis Corporation $ENOV

Deroy & Devereaux Private Investment Counsel Inc. bought a new position in shares of Enovis Corporation (NYSE:ENOV) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 109,960 shares of the company’s stock, valued at approximately $2,929,000.

Other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC boosted its stake in Enovis by 12.5% in the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after purchasing an additional 7,072 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Enovis by 37.6% in the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after acquiring an additional 73,116 shares in the last quarter. Empowered Funds LLC boosted its holdings in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after purchasing an additional 749 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares in the last quarter. Finally, Amundi lifted its holdings in shares of Enovis by 24,405.0% in the second quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after acquiring an additional 9,762 shares during the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Enovis

In related news, insider Oliver Engert purchased 1,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the completion of the purchase, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. This represents a 2.35% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders bought 5,000 shares of company stock valued at $121,983. Insiders own 2.70% of the company’s stock.

Analyst Upgrades and Downgrades

ENOV has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. William Blair initiated coverage on shares of Enovis in a research note on Friday. They issued an “outperform” rating for the company. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research note on Monday, March 30th. Wells Fargo & Company upgraded shares of Enovis to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, Evercore reiterated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $47.43.

Enovis Stock Up 4.5%

Shares of NYSE ENOV opened at $26.32 on Friday. The company has a 50 day simple moving average of $23.39 and a 200 day simple moving average of $26.40. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. Enovis Corporation has a 1 year low of $21.00 and a 1 year high of $37.85. The firm has a market cap of $1.51 billion, a PE ratio of -1.27 and a beta of 1.47.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. During the same period in the prior year, the company posted $0.98 EPS. The company’s revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts forecast that Enovis Corporation will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.